New eye drops promise quick redness relief in minutes
NCT ID NCT07578363
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This study tests an investigational eye drop (FID 123472) to see how well and how safely it reduces eye redness from minor irritations in adults. About 178 participants will receive either the active drop or a placebo (vehicle). The main goal is to measure redness reduction 15 minutes and 10 hours after the first dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 178 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form. * Willing and able to follow all instructions and attend all study visits. * History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion. * Baseline ocular redness score of 0.5 unit or higher in at least one eye at Visit 1 and greater than 1 unit on a 5-point scale in both eyes prior to randomization at Visit 2. * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol. * Ocular surgical interventions within 6 months prior to Visit 1 or during the study. * Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters. * Use of prohibited medications, devices, or treatments as specified in the protocol. * Out of range vital signs (blood pressure and/or pulse rate) as defined in the study protocol. * Abnormal intraocular pressure. * Other protocol-defined exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ocular hyperemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, 76134, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.